Contributes to Shaping Global Health Standards: Bio Farma and DCVMN Strengthens International Vaccine Collaboration

^{Pictured : DCVMN Supply Chain Working Group charts practical AI and partnership pathways in New Delhi.}

Bandung, October 24, 2025 — As part of its ongoing commitment to becoming a key player in the global vaccine industry, PT Bio Farma (Persero) continues to strengthen its contribution through active participation in the international network of the Developing Countries Vaccine Manufacturers Network (DCVMN). 2025 marks a significant milestone for Bio Farma, not only as the co-host of the 26th DCVMN Annual General Meeting (AGM), which will take place in Bali from October 29 to 31, 2025, but also through the company’s active engagement across DCVMN’s expert working groups.

Established in 2000, DCVMN serves as a strategic collaborative platform to enhance the vaccine self-reliance of developing countries through four main pillars: advocacy, training, partnership, and networking. Through advocacy, DCVMN amplifies the collective voice of vaccine manufacturers from developing countries in global health forums and with partners such as the WHO, Gavi, CEPI, UNICEF, Gates Foundation, PATH, and various funding agencies, championing equitable access to vaccines for all. In the area of training, the network builds members’ technical and managerial capacities through e-learning programs, workshops, hands-on training and technology-based skill development initiatives. The partnership pillar focuses on strategic collaboration to strengthen technology transfer, research innovation, and sustainable financing in vaccine development.

One of DCVMN’s most impactful initiatives is the establishment of expert working groups, which function as collaborative forums for experts from different DCVMN members, across countries, to design technical solutions, exchange best practices, and formulate policy recommendations related to vaccine quality testing, supply chain and traceability, clinical development, regulation, pharmacovigilance, and industry sustainability. Through these groups, experts play an essential role in strengthening global manufacturing standards, ensuring that vaccine production processes remain safe, efficient, and aligned with international best practices, and their perspectives are recognized by international fora. The working groups also serve as vital hubs for knowledge sharing, process standardization, and capacity building among vaccine manufacturers in developing countries.

DCVMN CEO, Rajinder Suri, states that DCVM members recorded more than 115 collaborations in the period of 2021 - 2025, out of those 41 were South-South Collaborations. On the other hand, DCVMN’s Working Groups bring the perspectives of vaccine manufacturers across developing countries into a clear, action-focused effort that shapes policy and builds practical capacity. By translating members’ inputs and real world challenges into evidence, training, and targeted dialogue with WHO and national regulators, the working groups produce tangible outputs that improve regulatory predictability, strengthen supply chains, and raise pharmacovigilance and industry sustainability. This year’s work ranges from an e-learning module on post approval changes and a PV maturity analysis supported by a joint workshop in New Delhi, to an air freight volumetrics study and a network survey resulting into a publication in a journal of repute documenting COVID 19 contributions of DCVMN members, alongside a strategic Healthy Industry Framework, that is working to develop matchmaking mechanism and Dashboard of Opportunities to guide funders and partners. Together, these activities ensure manufacturers’ realities inform decision making and help secure timely access to safe, affordable vaccines.

As a driving force in vaccine collaboration among developing countries, Bio Farma’s experts have played an active role in several of these working groups, contributing their knowledge and experience to shape global vaccine policies and practices. The Bio Farma experts involved include:

1. Rini Mulia Sari, Clinical Trial Working Group Team
2. Taufik Wilmansyah, Supply Chain Working Group Team
3. Acep Riza Wijayadikusumah, Design of Experiment (DoE) Working Group Team
4. Viska Indriani, Co-Chair Pharmacovigilance Working Group DCVMN
5. Indra Gunawan Setiadi, Manufacturing Science Working Group Team
6. Irma Riyanti, DCVMN 3R (Replace, Reduce, Refine) Working Group Team
7. Dea Marsendah, Training Working Group Team

Shadiq Akasya, President Director of Bio Farma, emphasized, “The active participation of Bio Farma’s experts in DCVMN’s expert working groups demonstrates that Indonesia is not merely a recipient of global health technology, but an integral contributor shaping new directions and standards in global vaccine development. It represents a tangible step toward equitable health independence and resilience.”

The involvement of Bio Farma’s experts across diverse technical areas reflects the company’s broad capabilities, not only as a leading vaccine manufacturer, but also as a center for research, regulation, supply chain management, and sustainable health industry development.

Bio Farma’s active participation in DCVMN’s working groups underscores the company’s long-term commitment to developing global talent and reinforcing Indonesia’s position as a hub of innovation and collaboration in vaccines and biotechnology.

Through the 26^th DCVMN AGM in Bali, Bio Farma and DCVMN reaffirm their shared mission to strengthen collaboration, drive innovation, and build a sustainable global health ecosystem, ensuring equitable and universal access to vaccines for all.

About DCVMN

The Developing Countries Vaccine Manufacturers Network (DCVMN) is a global alliance of 46 vaccine manufacturers from 17 developing countries, established in 2000 to strengthen public health through equitable access to high-quality vaccines.

DCVMN promotes collaboration among its members through advocacy, capacity building, professional training, and joint research initiatives, aimed at enhancing global immunization programs.

Working closely with international organizations such as WHO, UNICEF, GAVI, CEPI, PATH, CHAI, and the Gates Foundation, DCVMN strives to ensure that every nation has the capability to produce and supply affordable, life-saving vaccines. For further information, please visit dcvmn.org. 

About Bio Farma

PT Bio Farma (Persero) is Indonesia’s state-owned life science company and the largest vaccine manufacturer in Southeast Asia.

Founded in 1890 and headquartered in Bandung, Bio Farma produces and supplies vaccines to more than 150 countries, while playing an active role in biotechnology research, innovation, and global health security.

As a member of DCVMN, Bio Farma continues to contribute to international collaboration to ensure equitable vaccine access and improved global public health. For further information, please visit www.biofarma.co.id.